Table 3.
Trial site | Trial | Group | Current (stage III) | Planned accrual |
---|---|---|---|---|
UK, Australia, Denmark, Spain, Sweden, New Zealand | SCOT | CACTUS, OCTO | 3,295 | 4,000 |
Italy | TOSCA | GISCAD* | 2,389 | 2,500 |
France | IDEA | GERCOR, PRODIGE (FFCD – Unicancer) | 1,479 | 2,000 |
US | 80702 | CALGB/SWOG | 972 | 2,500 |
Greece | HORG | HORG | 432 | 1,000 |
Japan | ACHIEVE | JFMC | 230 | 1,200 |
Total | 6 trials | 16 groups | 8,797 | ≥10,500 |
SCOT, Short Course Oncology Treatment; TOSCA, Three or Six Colon Adjuvant; IDEA, International Duration Evaluation of Adjuvant Chemotherapy; CLEAR, Celecoxib and Length of Adjuvant Rx; HORG, Hellenic Oncology Research Group; ACHIEVE, Adjuvant Chemotherapy for colon cancer with HIgh EVidencE; CACTUS, Cancer Clinical Trials Unit Scotland; OCTO, Oncology Clinical Trials Office, APRIC, Associazione Per la RIcerca Clinica; GIRCG, Gruppo Italiano Ricerca Cancro Gastrico; *GISCAD and collaborating groups, Gruppo Italiano per lo Studio dei Carcinomi dell’Apparato Digerente; GOAM, Gruppo Oncologico Aree Metropolitane; GOCSI, Gruppo Oncologico del Centro Sud e lsole; GOCCI, Gruppo Oncologico Chirurgico Cooperativo Italiano; GOIRC, Gruppo Oncologico Italiano di Ricerca Clinica; GOIM, Gruppo Oncologico Italia Meridionale ; GONO, Gruppo Oncologico del Nord Ovest; IOR, Istituto Oncologico Romagnolo; ITMO, Italian Trials in Medical Oncology; SICOG, Southern Italy Cooperative Oncology Group; SICOG, Southern Italy Cooperative Oncology Group; GERCOR, Groupe Coopérateur Multidisciplinaire en Oncologie; PRODIGE, Partenariat de recherche en oncologie digestive; FFCD, Fédération Francophone de Cancérologie Digestive; CALGB, Cancer and Leukemia Group B; SWOG, Southwest Oncology Group; JFMC, Japanese Foundation for Multidisciplinary Treatment of Cancer